Home›Trial›NCT05131022
🔬NCT05131022Phase 1RECRUITING

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Study Summary

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Diffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Waldenstrom Macroglobulinemia (WM)Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
Interventions / Drugs
NX-5948
View on ClinicalTrials.gov ↗
Sponsor
NRIX
Nurix Therapeutics
Protein Degradation
D39/100
Study Details
Enrollment572 participants
Primary Completion—
Lead SponsorNurix Therapeutics, Inc.
Data Retrieved2026-04-11 04:22:54.408649+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.